Bryan Garnier - BASILEA PHARMACEUTICA (BSLN.S) BASILEA PHARMACEUTICA: Updated analysis of FIDES-01 1st cohort and rollout of the intensified 400mg dose regimen | BUY | CHF91(+107%)

Report

Bryan Garnier

Victor Floc’h

BASILEA PHARMACEUTICA: Updated analysis of FIDES-01 1st cohort and rollout of the intensified 400mg dose regimen | BUY | CHF91(+107%)

BASILEA PHARMACEUTICA - BUY | CHF91(+107%)
Updated analysis of FIDES-01 1st cohort and rollout of the intensified 400mg dose regimen

400mg/day intensified dose regimen expanded across the board
Updated analysis show further improvement from FIDES-01’s 1st cohort
Rich newsflow expected over the coming months

31/05/2021 1 EN

Underlying

BASILEA PHARMACEUTICA

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Victor Floc’h

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Bryan Garnier

BASILEA PHARMACEUTICA (BUY, TP CHF91) | Positive phase III results for Cresemba in Japan

July 26, 2021 July 26, 2021 3 EN

Bryan Garnier

BASILEA (BUY, TP CHF91) | Lisavanbulin’s market opportunity strengthened by new epidemiology data

June 7, 2021 June 7, 2021 1 EN

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Yesterday, we hosted an exclusive fireside chat at our Paris HQ with ONWARD's co-founders, Dr. Grégoire Courtine and Dr. Jocelyne Bloch, accompanied by institutional investors, to learn about the professional endeavours that led them to jump from researchers to entrepreneurs, with a special deep-di

April 25, 2025 April 25, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: joint-development progress in textiles

Yesterday, Avantium announced the successful development of a PEF-based spacer fabric in collaboration with partners Auping, Muller Textiles, Antex and Monosuisse. This breathable, cushioning 3D material marks a step forward for this partnership, ongoing since 2024, aiming to create PEF-based yarns

April 25, 2025 April 25, 2025 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

A recent publication in Nature Communications (Groeneweg, van Geest et al. 2025) highlights the broad therapeutic applicability of Emcitate across the heterogeneity of the MCT8 deficient target group and supporting its uniform treatment eligibility across a genetically diverse patient population. I

April 25, 2025 April 25, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BASILEA PHARMACEUTICA: Updated analysis of FIDES-01 1st cohort and rollout of the intensified 400mg dose regimen | BUY | CHF91(+107%)

Monthly LMI Update Independent Investment Research

BASILEA PHARMACEUTICA (BUY, TP CHF91) | Positive phase III results for Cresemba in Japan

BASILEA (BUY, TP CHF91) | Lisavanbulin’s market opportunity strengthened by new epidemiology data

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Avantium: joint-development progress in textiles

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe